Teriparatide NEW
| Price | $1600 |
| Package | 1mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: Teriparatide | CAS No.: 52232-67-4 |
| Supply Ability: 10g | Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | Teriparatide |
| Description | Teriparatide is an agonist of PHT(IC50 of 2 nM in HEK293 cells). |
| In vivo | In Teriparatide-treated animals, Trabecular bone calcium and dry weight of the distal femur increased significantly. The increase in trabecular calcium compared with vehicle control occurred as early as 1 week after initiation of treatment with a 35% and 45% increase, respectively, for 10 μg/kg and 40 μg/kg Teriparatide. Similar results were observed for trabecular dry weight. After 4 weeks of treatment with 10 mg/kg or 40 mg/kg Teriparatide, trabecular calcium increased significantly by 70% and 123%, respectively, compared with the vehicle and by 73%. The 4-week Teriparatide administration + 8-week vehicle administration decrease the pore ratio, number, and density as well as the cortical area and thickness, compared with the 4-week Teriparatide administration, but the pore ratio, cortical area, and thickness are still higher compared with the 12-week vehicle administration. The 4-week Teriparatide administration increase the pore ratio, number, and density as well as the cortical area, thickness, and bone mineral content (BMC), without significant influencing the volumetric bone mineral density (BMD). The 4-week Teriparatide administration + 8-week higherdose IBN administration increase the cortical area, thickness, BMC, and volumetric BMD and decrease the pore ratio, but not the pore number or density, compared with the 4-week Teriparatide administration + 8-week vehicle administration. |
| Storage | Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 50 mg/mL (12.14 mM), Sonication is recommended. |
| Keywords | Teriparatide | PTH | Human parathyroid hormone | hPTH |
| Inhibitors Related | Propylthiouracil | Azetirelin | Resmetirom | 2,2-BIS(2-HYDROXY-5-BIPHENYLYL)PROPANE | Iopanoic acid | DS08210767 | Carbimazole | Octinoxate | Methimazole | PCO371 | Tiratricol | Eneboparatide |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
Sinoway Industrial co., ltd.
|
2026-06-30 | ||
|
VIP2Y
|
Xi an Biohorlden Industry Trade Co Ltd
|
2026-06-30 | ||
| $5.00 |
VIP2Y
|
Hebei Jiafan Trading Company Limited
|
2026-06-30 | |
| $1.00 |
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-30 | |
|
VIP2Y
|
Shandong Huizhihan Supply Chain Co., Ltd
|
2026-06-30 | ||
| $100.00 |
VIP2Y
|
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
|
2026-06-30 | |
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2026-06-30 | ||
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-06-30 | ||
|
VIP3Y
|
Shandong Hanjiang Chemical Co., Ltd
|
2026-06-25 | ||
|
VIP2Y
|
Shaanxi Xianhe Biotech Co., Ltd
|
2026-06-23 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY